ENTITY
Shanghai Fosun Pharmaceutical (Group)

Shanghai Fosun Pharmaceutical (Group) (2196 HK)

125
Analysis
Health CareChina
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical company. Through its subsidiaries, the Company manufactures genetic medicines, Chinese traditional medicines, diagnostic products, and medical instruments, provides technology, marketing, and advertising services, as well as invests in import and export trading.
more
Refresh
14 Sep 2019 11:52

HK Short Interest - Diverging Healthcare

We analyse the latest SFC data released Friday evening on short position reporting in Hong Kong for the week ended 6 September.Total short notional...

Logo
401 Views
Share
13 Sep 2019 11:27

Shanghai Henlius (复宏汉霖) IPO: Newsflow on HLX10 Clinical Trial and ASEAN Commercialization

Shanghai Fosun Pharmaceutical (Group) (2196 HK), the parent company of Shanghai Henlius which in the process of book building today to raise up to...

Logo
551 Views
Share
11 Sep 2019 15:34

Shanghai Henlius Biotech IPO: Valuation Prescribed at Low-End

Shanghai Henlius Biotech (2696 HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) (2196...

Logo
509 Views
Share
26 Aug 2019 14:32

Shanghai Henlius Biotech IPO: Cash Breakeven Analysis

Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...

Logo
412 Views
Share
22 Aug 2019 11:21

Shanghai Henlius (复宏汉霖) IPO: Thoughts on Valuation

Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In our previous insights covering Shanghai Henlius, we have...

Logo
561 Views
Share
x